1. Introduction {#sec1-marinedrugs-16-00259}
===============

The marine environment is a valuable source of natural products (NPs) with increasing medical importance \[[@B1-marinedrugs-16-00259],[@B2-marinedrugs-16-00259]\]. The relevance and success of screening programs aimed at discovering new molecules with pharmaceutical application from the marine environment has been validated by the development and marketing of various NPs as analgesic \[[@B3-marinedrugs-16-00259]\], antiviral \[[@B4-marinedrugs-16-00259]\] and antitumor drugs \[[@B5-marinedrugs-16-00259]\]. This fact, along with the exponentially growing number of reported bioactive agents isolated from marine invertebrates and microorganisms \[[@B6-marinedrugs-16-00259],[@B7-marinedrugs-16-00259]\], points to oceans as a preeminent environment for the supply of novel therapeutic chemicals. Although marine invertebrates such as sponges \[[@B8-marinedrugs-16-00259],[@B9-marinedrugs-16-00259]\] are renowned drug discovery targets, in many instances the true producer of the relevant NP are symbiotic microorganisms, often bacteria and cyanobacteria, which represent a worthy exploring source of novel and structurally diverse chemical entities \[[@B10-marinedrugs-16-00259],[@B11-marinedrugs-16-00259],[@B12-marinedrugs-16-00259],[@B13-marinedrugs-16-00259]\].

In the last decade, much attention has been given to microbial genomics regarding the potential of microorganisms as producers of bioactive metabolites \[[@B14-marinedrugs-16-00259],[@B15-marinedrugs-16-00259],[@B16-marinedrugs-16-00259]\]. Many whole-genome sequencing projects from both marine- and soil-derived microorganisms have uncovered a wealth of orphan genes related to secondary metabolism such as polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS) \[[@B17-marinedrugs-16-00259],[@B18-marinedrugs-16-00259]\]. This way, the blooming number of microbial genomes and metagenomic data from different environments \[[@B19-marinedrugs-16-00259],[@B20-marinedrugs-16-00259],[@B21-marinedrugs-16-00259]\] might contribute to innovative achievements on NP research and raises new prospects for the discovery of novel treatments for emerging disorders \[[@B22-marinedrugs-16-00259],[@B23-marinedrugs-16-00259],[@B24-marinedrugs-16-00259]\]. Genomic analysis of known and under study microorganisms reveals that the number of potential secondary metabolite gene clusters harbored by their respective chromosomes surpasses the amount of compounds detected under conventional laboratory conditions, indicating that microbial capability to provide chemicals of medical interest could be far greater than expected \[[@B25-marinedrugs-16-00259],[@B26-marinedrugs-16-00259],[@B27-marinedrugs-16-00259]\]. This has prompted the development of a series of molecular- and cultivation-based approaches intended to uncover and exploit the natural chemical potential of candidate microorganisms by eliciting the expression of silent or poorly expressed gene clusters \[[@B28-marinedrugs-16-00259],[@B29-marinedrugs-16-00259],[@B30-marinedrugs-16-00259],[@B31-marinedrugs-16-00259],[@B32-marinedrugs-16-00259]\]. Alone or in combination, different pathway-specific genome mining strategies such as gene mutation, insertion of constitutive promoters in front of key gene operons or direct cloning and subsequent heterologous expression of orphan gene clusters, might help to uncover the metabolite(s) biosynthesized by any given cryptic gene cluster. These and many other molecular strategies, along with the development of next-generation whole-genome sequencing systems and bioinformatics sequence analysis platforms, have given birth to the so-called field of genomics-driven natural product discovery \[[@B24-marinedrugs-16-00259],[@B33-marinedrugs-16-00259],[@B34-marinedrugs-16-00259]\]. Research on this field has made feasible the discovery of a wave of novel microbial NPs biosynthesized by gene clusters regarded up to now as cryptic \[[@B35-marinedrugs-16-00259],[@B36-marinedrugs-16-00259],[@B37-marinedrugs-16-00259],[@B38-marinedrugs-16-00259],[@B39-marinedrugs-16-00259],[@B40-marinedrugs-16-00259],[@B41-marinedrugs-16-00259]\].

Herein, we report on the activation of a cryptic PKS-NRPS hybrid gene cluster in the chromosome of the marine actinobacteria *Streptomyces caniferus* GUA-06-05-006A. This has enabled the identification of three novel metabolites belonging to the jomthonic acid (JA) family of NPs. Up to date, only three members (JA A--C) of this family of molecules have been reported \[[@B42-marinedrugs-16-00259],[@B43-marinedrugs-16-00259]\]. We describe the isolation and structural determination of two new JA A derivatives, and the identification of additional potential related compounds.

2. Results {#sec2-marinedrugs-16-00259}
==========

2.1. Identification of the Jomthonic Acid Gene Cluster {#sec2dot1-marinedrugs-16-00259}
------------------------------------------------------

Previous identification and characterization in the marine actinobacteria *S. caniferus* GUA-06-05-006A of the promising antitumor compounds PM100117 and PM100118 biosynthesis gene cluster (BGC) \[[@B44-marinedrugs-16-00259]\], aimed us to further investigate the chemical diversity enclosed in this strain. Of the 32 BGCs potentially involved in the production of secondary metabolites detected after sequencing of the genome of *S. caniferus* GUA-06-05-006A, only two BGCs contain PKS--NRPS hybrid genes \[[@B44-marinedrugs-16-00259]\]. One of these PKS--NRPS BGCs ([Figure 1](#marinedrugs-16-00259-f001){ref-type="fig"}, [Table 1](#marinedrugs-16-00259-t001){ref-type="table"}) caught our attention because it entails a large operon that included a gene (*jomM*) coding for a putative methyltransferase highly identical to MppJ, the enzyme responsible for the biosynthesis of βMePhe in *Streptomyces hygroscopicus* \[[@B45-marinedrugs-16-00259]\]. To discover the compound(s) coded by this BGC, we inserted the constitutive promoter *ermE\*p* upstream of the PKS gene *jomP1* ([Figure 1](#marinedrugs-16-00259-f001){ref-type="fig"}). Ultra Performance Liquid Chromatography (UPLC) analysis of metabolite production in the resulting strain, G-p*ermE\**, revealed the increased biosynthesis, relative to wild type, of three compounds (**1**--**3**, [Figure 2](#marinedrugs-16-00259-f002){ref-type="fig"}A) showing identical UV spectra, with a maximum absorption wavelength at 264 nm. Consistent with this observation, production of **1**--**3** was abolished upon insertional inactivation of PKS gene *jomP1* or NRPS gene *jomN* ([Figure 2](#marinedrugs-16-00259-f002){ref-type="fig"}A), thus confirming the involvement of both genes in **1**--**3** biosynthesis. These compounds were purified and subjected to structural analysis by nuclear magnetic resonance NMR ([Supplementary file 1](#app1-marinedrugs-16-00259){ref-type="app"}). The chemical structure of **1** and **2** corresponded to novel analogues of JA A, a previously identified natural product with adipogenic activity produced by *Streptomyces* sp. BB47 \[[@B42-marinedrugs-16-00259]\]. Structurally, JA A (peak **3**, UPLC *R~t~* = 5.209 min, *m*/*z* 388.2141\[*M* + H\]^+^ (calculated for C~22~H~30~NO~5~ 388.2118)), consists of a βMePhe residue with its amino and carboxyl group attached to a short polyketide chain and to a hydroxyacid unit, respectively ([Figure 2](#marinedrugs-16-00259-f002){ref-type="fig"}B). The chemical structure of **1** (UPLC *R~t~* = 4,264 min, *m*/*z* 516.2709 \[*M* + H\]^+^ (calculated for C~27~H~38~N~3~O~7~ 516.2704)) is that of JA A with a glutamine residue at C21 in the hydroxyacid part. Compound **2** (UPLC *R~t~* = 4,411 min, *m*/*z* 404.2099 \[*M* + H\]^+^ (calculated for C~22~H~30~NO~6~ 404. 2079)) is derived from **3** by polyketide chain hydroxylation at C1. Given the structural relationship of compounds **1** and **2** with JA A, hereinafter, they will be referred to as JA D and E, respectively.

2.2. Bioinformatics Analysis of the Jomthonic Acid Gene Cluster and Proposed Biosynthesis Pathway {#sec2dot2-marinedrugs-16-00259}
-------------------------------------------------------------------------------------------------

*Polyketide biosynthesis*: The predicted JAs BGC spans 55kb and contains 38 ORFs, which includes two putative PKS genes, *jomP1* and *jomP2* ([Figure 1](#marinedrugs-16-00259-f001){ref-type="fig"} and [Table 1](#marinedrugs-16-00259-t001){ref-type="table"}), presumably involved in the biosynthesis of the JA polyketide chain. JomP1 and JomP2 show the closest similarity with PKS proteins StiA (57%) and StiC (49%), respectively, which participate in the biosynthesis of stigmatellin in the myxobacteria *Stigmatella aurantica* Sga15 \[[@B46-marinedrugs-16-00259]\]. Besides, both proteins show resemblance with putative PKS enzymes from other myxobacteria members and several species of cyanobacteria. Bioinformatics analysis detected in JomP1 an uncommon PKS domain pattern, consisting of two ACP and two contiguous AT (AT~1~ and AT~2~) domains, distributed as follows: ACP-KS-AT~1~-AT~2~-KR-ACP ([Figure 3](#marinedrugs-16-00259-f003){ref-type="fig"}). This pattern is a rare finding previously described in myxobacteria \[[@B46-marinedrugs-16-00259],[@B47-marinedrugs-16-00259],[@B48-marinedrugs-16-00259],[@B49-marinedrugs-16-00259]\]. In these microorganisms, the presence of two adjacent AT domains has been linked to the specificity of the loading domain for unusual initiating units, alternative to malonyl- and methylmalonyl-CoA \[[@B46-marinedrugs-16-00259]\]. It has been conjectured that in the biosynthesis of myxalamid \[[@B48-marinedrugs-16-00259]\], soraphen \[[@B49-marinedrugs-16-00259]\] and myxothiazol \[[@B47-marinedrugs-16-00259]\], the first AT domain is responsible for loading the unusual starter units, isobutyryl-CoA/2-methyl-butyryl-CoA, benzoyl-CoA and methylbutyryl-CoA, respectively, while the second AT domain is involved in the transfer of the first extension unit, typically malonyl- or methylmalonyl-CoA. However, this assumption might not stand for the JomP1 AT~2~ domain, which might be inactive due to the substitution of Ser-7 and Gln-8 for Gly and His, respectively, in the conserved sequence domain GqgSQ ([Supplementary file 2: Figure S22](#app1-marinedrugs-16-00259){ref-type="app"}) that lies close to the active site pocket in the AT domain 3D model \[[@B50-marinedrugs-16-00259],[@B51-marinedrugs-16-00259]\]. According to these observations, it seems reasonable to propose the transfer by AT~1~ of 2-methyl-2-eno-butyryl-CoA (MEB-CoA) as the carboxylic acid incorporated by JomP1 ([Figure 3](#marinedrugs-16-00259-f003){ref-type="fig"}). Furthermore, a certain degree of flexibility of AT~1~ could explain the biosynthesis of other JAs previously described \[[@B42-marinedrugs-16-00259],[@B43-marinedrugs-16-00259]\]. In this hypothetical model, no role can be envisaged for the JomP1 KR domain. The biosynthesis of the JAs polyketide chain is completed by PKS JomP2, which contains an AT domain with predicted specificity for malonyl-CoA, KR and DH domains.

*Methylphenylalanine biosynthesis*: A (2S, 3R) βMePhe residue constitutes the structural core of JAs. Biosynthesis of this moiety presumably requires activity of a methyltransferase enzyme. Genetic experiments in *Streptomyces hygroscopicus* NRRL30439 have shown methyltransferase MppJ to catalyze phenylalanine β-methylation in mannopeptimycin biosynthesis \[[@B45-marinedrugs-16-00259]\]. Besides, later in vitro studies on MppJ activity have shown that it methylates the benzylic C atom of phenylpyruvate instead of phenylalanine or the mannopeptimycin aglycone F \[[@B52-marinedrugs-16-00259]\]. Gene *jomM* in the JAs BGC codes for a putative methyltranferase 55% identical to MppJ. UPLC analysis of culture extracts from deletion mutant ∆*jomM* showed loss of **1**--**3** production ([Figure 4](#marinedrugs-16-00259-f004){ref-type="fig"}), confirming involvement in JAs biosynthesis, conceivably catalyzing phenylalanine β-methylation. JA biosynthesis was restored in ∆*jomM* upon *jomM* re-introduction ([Supplementary file 2: Figure S23](#app1-marinedrugs-16-00259){ref-type="app"}).

*2-methyl-3-hydroxybutyrate biosynthesis and other gene functions*: Various branched-chain fatty acids, such as 2-methylbutyrate, can be generated in bacteria from amino acid fermentation. Moreover, interconversion between 2-methy-3-hydroxylbutyrate (MHB) and leucine has been described in anaerobic bacteria \[[@B53-marinedrugs-16-00259],[@B54-marinedrugs-16-00259]\]. Hence, although based on sequence identity, no gene functions remotely related to MHB biosynthesis are comprised within the JA BGC; certain primary metabolism reactions might supply this structural moiety.

The JA BGC also comprises NRPS *jomN*, containing a condensation and an adenylation domain, which is postulated to be the candidate enzyme to catalyze βMePhecondensation with the polyketide chain. MbtH-like protein JomB and thioesterase JomT complete the proteins presumably required for JAs biosynthesis. Based on various studies on MbtH-like protein function \[[@B55-marinedrugs-16-00259],[@B56-marinedrugs-16-00259]\], JomB is possibly required for βMePhe activation during its adenylation by JomN. JomT might be required to cleave and offload JA F from the JomN PCP domain ([Figure 3](#marinedrugs-16-00259-f003){ref-type="fig"}).

*Hypothetical model for JAs assembly*: Polyketide biosynthesis might be commenced by JomP1 which, despite containing two ACP and two AT domains, would only be responsible for the loading of the starting carboxylic acid MEB ([Figure 3](#marinedrugs-16-00259-f003){ref-type="fig"}). As explained above, no extension reaction is presumed to be catalyzed by JomP1 AT~2~. JomP2 would then extend the polyketide chain with malonate, with a double bond formation due to the consecutive activity of its KR and DH domain. Next, NRPS JomN would perform condensation of βMePhe with the polyketide molecule to form JA F. Subsequent addition of MHB to form JA A might require JA F release from JomN, a reaction probably catalyzed by JomT. Notwithstanding, the enzymatic activity (X~1~) required to transfer the third JAs structural moiety MHB to JA F ([Figure 3](#marinedrugs-16-00259-f003){ref-type="fig"}) is unknown and possibly coded elsewhere in the genome as, based on sequence identity, no gene functions suited to accomplish this reaction have been identified within the JA BGC. Likewise, the JA BGC does not code for enzymatic activities related to glutamine transfer (X~2~) to produce JA D and JA hydroxylation (X~3~) to produce JA E ([Figure 3](#marinedrugs-16-00259-f003){ref-type="fig"}). Gene candidates conceivably involved is those reaction are *orf31* and *orf9*, which encode for putative proteins with glutamine binding lipoprotein and monooxygenase activity, respectively. Nevertheless, deletion of these genes does not have any effect on JA D and E production ([Figure 4](#marinedrugs-16-00259-f004){ref-type="fig"}).

2.3. Cluster Boundaries Analysis {#sec2dot3-marinedrugs-16-00259}
--------------------------------

Flanking the JAs BGC there are four *orfs* coding for putative transcriptional regulators belonging to the GntR (*orf29*), MarR (*orf20*), LuxR (*orf16*) and AraC (*orf8*) families of transcription factors. To examine whether or not these putative regulators take part in JAs biosynthesis control, we generated a series of single gene deletion strains. UPLC metabolite analysis of the resulting mutants ∆*orf29-gntR*, ∆*orf20-marR* and ∆*orf16-luxR*, revealed no significant alteration of JAs biosynthesis with respect to wild type cells ([Figure 5](#marinedrugs-16-00259-f005){ref-type="fig"}A). By contrast, mutant ∆*orf8-araC* showed a slight increase of **1** and **2** production, concomitant with a diminished JA A level. As a second assessment of the potential involvement of these genes in JAs biosynthesis, they were ectopically expressed under the control of the constitutive promoter *ermE\**p from the integrative plasmid pSETk. The resulting constructs pSAraC, pSLuxR, pSMarR and pSGntRwere were transferred to wild type *S. caniferus* GUA-06-05-006A to produce the recombinant strains G-pSAraC, G-pSLuxR, G-pSMarR and G-pSGntR, respectively, which were likewise subjected to metabolite production analysis ([Figure 5](#marinedrugs-16-00259-f005){ref-type="fig"}B). Overexpression of *orf29* (G-pSGntR) resulted in JAs biosynthesis abrogation and a severe impairment of PM100117/18 production, indicating the pleiotropic effect possibly exerted by this gene on metabolite production. This observation, along with the unaltered biosynthesis of compounds **1** and **2** upon *orf29* deletion, makes us to consider that this *orf* lies outside the JAs biosynthesis gene cluster. Pleiotropic effects on PM100117/18 biosynthesis are similarly observed in recombinant strains G-pSLuxR (*orf16*) and G-pSMarR (*orf20*), but neither these strains nor G-pSAraC (*orf8*) showed altered **1** and **2** biosynthesis levels relative to control. Under the light of these observations, it is not possible to determine whether *orf8* and *orf29* play a direct role or simply exert a pleiotropic effect on JAs biosynthesis.

The right boundary of the JAs gene cluster is thus defined by *jomM*, as the adjacent *orf16* does not seem to be involved in JAs biosynthesis. This side of the cluster also comprises putative gene functions connected to chemical detoxification (*orf21* and *orf30*), DNA cleavage and repair (*orf19* and *orf22*) and primary metabolism processes, such as sugar metabolism and transport (*orf24*-*orf28*) and nitrogen metabolism (*orf31* and *orf32*). The left limit of the cluster might be defined by *jomP1*, whose adjacent *orf14* and *orf15* encode for hypothetical and unassigned function proteins, respectively. Besides, this flank of the JAs gene cluster contains miscellanea of hypothetical gene functions related to virulence (*orf4*, *orf7* and *orf11*), cell division (*orf3*) and cell signaling (*orf10*) among others ([Table 1](#marinedrugs-16-00259-t001){ref-type="table"}).

2.4. Heterologous Expression of the JAs BGC {#sec2dot4-marinedrugs-16-00259}
-------------------------------------------

In order to confirm the involvement of the proposed gene cluster in JA biosynthesis, a DNA fragment spanning from *orf9* to *orf24* was cloned using the transformation-associated recombination (TAR) cloning system \[[@B37-marinedrugs-16-00259]\] and the resulting construct, pJATAR, was transferred to the heterologous hosts *Streptomyces coelicolor* M1152 and *Streptomyces albus* J1074 to produce strains Sc-pJATAR and Sa-pJATAR, respectively. These strains were fermented in a culture medium that favors secondary metabolite biosynthesis in their respective backgrounds. Analysis by UPLC of organic extracts from the resulting cultures did not detect traces of JAs ([Figure 6](#marinedrugs-16-00259-f006){ref-type="fig"}). This result led us to hesitate on the expression in the heterologous hosts of genes presumably required for JAs biosynthesis. Thus, we manipulated pJATAR to insert the constitutive promoter *ermE\*p* in front of *jomP1* to compel transcription of genes *jomP1*-*jomM*, which possibly constitutes a single transcriptional unit. Likewise, the resulting plasmid, pJATARe, was introduced in *S. coelicolor* M1152 and *S. albus* J1074, generating strains Sc-pJATARe and Sa-pJATARe, respectively. Following UPLC analysis of metabolite production the presence of JA A biosynthesis was detected in both recombinant strains ([Figure 6](#marinedrugs-16-00259-f006){ref-type="fig"}). Besides, based on absorption spectra resemblance, strain Sa-pNTARe produced two additional potential JAs family members, peaks 1^a^ and 2^a^ ([Figure 6](#marinedrugs-16-00259-f006){ref-type="fig"}B). Mass spectra of these products are shown in [Supplementary file 2: Figure S24](#app1-marinedrugs-16-00259){ref-type="app"}. Molecular weight of product 2^a^ matched that of JA B/C (*m*/*z*374 \[*M*+H\]^+^) ([Figure 6](#marinedrugs-16-00259-f006){ref-type="fig"}C), which remained undetected in the natural producer *S. caniferus* GUA-06-05-006A ([Figure 2](#marinedrugs-16-00259-f002){ref-type="fig"}). Later metabolite analysis of 5-fold concentrated culture extracts from the *S. caniferus* GUA-06-05-006A derivative strain *G-permE\** led to the detection, by absorption spectra resemblance, of other potential JA candidates, including JA F ([Supplementary file 2: Figure S25](#app1-marinedrugs-16-00259){ref-type="app"}), but not JA B/C. Given their low production levels, purification of these compounds did not yield the product quantities required to carry out NMR analysis.

3. Discussion {#sec3-marinedrugs-16-00259}
=============

Given their adipogenic activity, JAs constitute a promising family of NPs in metabolic disorders research \[[@B57-marinedrugs-16-00259],[@B58-marinedrugs-16-00259],[@B59-marinedrugs-16-00259]\]. JA's chemical structure contains interesting structural moieties also reported in other metabolites. For instance, the JA A short polyketide chain is identical to that of salinamide C from *Streptomyces* sp. CNB-091 \[[@B60-marinedrugs-16-00259]\] and daldinin F from *Hypoxylonfuscum* \[[@B61-marinedrugs-16-00259]\]. Likewise, βMePhe is an unusual non-proteinogenic amino acid previously described as part of the altemicidin derivative SB-203208 \[[@B62-marinedrugs-16-00259]\], bottromycins \[[@B63-marinedrugs-16-00259]\], AK toxin \[[@B64-marinedrugs-16-00259]\], homaomycin \[[@B65-marinedrugs-16-00259]\] and mannopeptimycin \[[@B66-marinedrugs-16-00259]\]. However, only the latter two compounds share with JAs the 3R configuration of the βMePhe stereocenter.

Following a molecular elicitation strategy, we have identified the JA BGC, which has been characterized based on bioinformatics analysis and genetic engineering data. The proposed cluster covers 17.1 Kb and contains six biosynthesis genes comprised between *jomP1* and *jomM*, coding for putative functions required for polyketide biosynthesis and phenylalanine methylation. PKS JomP1 displays an uncommon structure, consisting of two ACP domains and two adjacent AT domains, up to date only reported in members of myxobacteria \[[@B46-marinedrugs-16-00259],[@B47-marinedrugs-16-00259],[@B48-marinedrugs-16-00259],[@B49-marinedrugs-16-00259]\]. For similar myxobacterial PKS genes, a mechanism by which the first AT domain transfers an unconventional starting unit and the second AT domain transfer either malonyl- or methylmalonyl-CoA has been proposed. However, if JomP1 operated through this mechanism, it would be arduous to assess the type of starting and elongation units employed to synthesize the short polyketide chain present in JAs. Tentatively, we could postulate malonyl- and methylmalonyl-CoA as starting and extension molecules, respectively, which along with latter condensation to malonyl-CoA catalyzed by JomP2 could generate the JA polyketide chain with an extra hydroxyl group at C2 ([Supplementary file 2: Figure S26](#app1-marinedrugs-16-00259){ref-type="app"}). Instead, based on the sequence of conserved domain, we have considered plausible the inactivity of AT~2~ and transfer of MEB-CoA by AT~1~ domain ([Figure 3](#marinedrugs-16-00259-f003){ref-type="fig"}).

Despite the absence of information on various gene functions presumably required for JA biosynthesis, we have intuitively outlined a biosynthesis pathway ([Figure 3](#marinedrugs-16-00259-f003){ref-type="fig"}). Although no traces of JA B and C have been detected in *S. caniferus* GUA-06-05-006A, biosynthesis of both compounds could occur through similar reaction steps as JA A when 2-eno-butyrate and 3-hydroxybutyrate are available as substrates for JomP1 and enzyme X~1~, respectively ([Figure 3](#marinedrugs-16-00259-f003){ref-type="fig"}). Based on predicted gene functions, enzymes relevant to MHB transfer seem to be absent from the predicted JAs BGC. Thus, according to the enzymatic activities encoded within the proposed biosynthesis pathway, it could be reasonable to consider JA F as the true pathway end product, and the other JAs family members as pathway shunt metabolites. Interestingly, heterologous expression of the BGC led to the biosynthesis of an array of JAs in *S. albus* J1074, including JA A and possibly JA B or C. Whether the enzymatic activity required for MHB transfer to JA F has been provided in the heterologous DNA fragment (unlikely) or, on the contrary, is integrated in the host genome is unknown. Detection of additional JA derivatives in a heterologous host reinforces the idea that the biosynthetic machinery harbored in different actinobacteria lineages can be successfully combined and exploited to generate structural diversity.

Expression of the JA BGC seems to be regulated, as no JAs are detected in the heterologous host unless its biosynthesis is elicited by *ermE\*p* insertion upstream of *jomP1*. Gene deletion and overexpression experiments have not demonstrated the direct involvement of putative transcriptional regulators coded in the surroundings of *jomP1*-*jomM* on JAs biosynthesis control. Hence, based on these results, presence of key regulators encoded outside the JAs BGC is foreseeable. Lack of essential gene functions in BGC is frequently explained on the basis of large-scale genetic rearrangements, such as inversions and transpositions, which are fundamental to genome evolution \[[@B67-marinedrugs-16-00259],[@B68-marinedrugs-16-00259]\].

This work provides a first insight into the genetic bases of JAs biosynthesis and shows heterologous expression of BGCs as a suitable strategy to generate additional structural diversity. Moreover, availability of the JAs BGC enables further genetic manipulations aimed at generating novel derivatives with improved pharmacological properties and eases the elucidation of unraveled biosynthesis steps.

4. Materials and Methods {#sec4-marinedrugs-16-00259}
========================

4.1. Strains, Tumor Cell Lines, Media and Cultivation Conditions {#sec4dot1-marinedrugs-16-00259}
----------------------------------------------------------------

*Streptomyces* strains *S. caniferus* GUA-06-05-006A \[[@B69-marinedrugs-16-00259]\], *S. coelicolor* M1152 \[[@B70-marinedrugs-16-00259]\] and *S. albus* J1074 \[[@B36-marinedrugs-16-00259]\] were routinely maintained in medium A (MA) \[[@B71-marinedrugs-16-00259]\]. Metabolite production analyses and large scale fermentations in *S.caniferus* GUA-06-05-006A were performed in SMS medium as described elsewhere \[[@B44-marinedrugs-16-00259]\]. Heterologous production of JAs in *S. coelicolor* M1152 and *S. albus* J1074 was achieved after 3 days of cultivation at 30 °C in GYM \[[@B72-marinedrugs-16-00259]\] and R5A medium \[[@B71-marinedrugs-16-00259]\], respectively. *Escherichia coli* strains DH10B \[[@B73-marinedrugs-16-00259]\], used for cloning, ET12567/pUB307 \[[@B74-marinedrugs-16-00259]\] and ET12567/pUZ8002 \[[@B75-marinedrugs-16-00259]\], used for intergeneric conjugation, were grown in LB or 2× TY medium, supplemented with the appropriate antibiotic for plasmid selection \[[@B74-marinedrugs-16-00259]\].

Yeast strain *Saccharomyces cerevisiae* VL6-48 (MAT alpha, his3-D200, trp1-D1, ura3-52, lys2, ade2-101, met14, psi + cir0), used for TAR cloning, was grown in YPD or YNB-trp medium \[[@B76-marinedrugs-16-00259]\], made solid, when required, by addition of 2% agar.

4.2. DNA Manipulation {#sec4dot2-marinedrugs-16-00259}
---------------------

DNA manipulation in *Escherichia coli* and *S. caniferus* GUA-06-05-006A was carried out according to standard protocols \[[@B74-marinedrugs-16-00259],[@B77-marinedrugs-16-00259]\]. Polymerase chain reaction (PCR) amplifications were performed by using Herculase II Fusion polymerase (Agilent Technologies, Palo Alto, CA, USA) with a previously reported touchdown PCR procedure \[[@B44-marinedrugs-16-00259]\]. All primers used in this work are described in [Supplementary file 3: Table S1](#app1-marinedrugs-16-00259){ref-type="app"}. Genetic manipulations in *S. caniferus* GUA-06-05-006A were confirmed by colony PCR by using the procedure described in \[[@B78-marinedrugs-16-00259]\] with the following modifications. Bacterial colonies were suspended in 50 μL of 0.2 M 2-\[\[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl\]amino\] ethanesulfonic acid (TES) buffer, pH 7.5, with 1 μL lysozyme (50 mg/mL) and incubated for 40 min at 30 °C. The mix was centrifuged (10,000× *g*, 2 min) and the pellet thoroughly suspended in 10 μL dimethyl sulfoxide (DMSO). The resulting suspension (2 μL) was used as PCR template with the indicated primer pairs ([Supplementary file 3: Table S1](#app1-marinedrugs-16-00259){ref-type="app"}).

4.3. Plasmids Construction and Strain Generation {#sec4dot3-marinedrugs-16-00259}
------------------------------------------------

Information relevant to plasmids generated in this work is summarized in [Supplementary file 3: Table S1](#app1-marinedrugs-16-00259){ref-type="app"}. All plasmids were transferred to *S.caniferus* GUA-06-05-006Aby intergeneric conjugation as previously described \[[@B44-marinedrugs-16-00259]\]. For *jomP1* and *jomN* insertional inactivation, internal gene fragments were amplified with the primer pairs EcoRI-P1/ HindIII-P1 and EcoRI-N/ HindIII-N, respectively, and cloned in the indicated restriction sites of plasmid pOJ260 \[[@B79-marinedrugs-16-00259]\], which lacks the capacity to replicate in *Streptomyces* and carries the *aac*(*3*)*IV* gene marker that confers resistance to apramycin(Am^R^). The resulting plasmids, pIjomP1 and pIjomN, were then transferred to *S.caniferus* GUA-06-05-006A to produce strains ∆*jomP1* and ∆*jomN*, respectively. Insertion of *ermE\*p* upstream of *jomP1* was performed in the pOJ260 derivative pOJ260e as described in \[[@B36-marinedrugs-16-00259]\]. A 2.8 Kb fragment covering the *jomP1* upstream region, including 108 bp from the start codon, was amplified with primers EcoRI-EP1/PstI-EP1 and cloned in pOJ260e to afford plasmid pEjomP1, which was used to generate strain G-p*ermE*\*.

To accomplish single deletion of *orf8*, *orf9*, *orf16*, *orf20*, *orf29*, *orf31* and *jomM*, the downstream DNA sequence of the referred target genes were amplified with the primer pairsBamHI-orf8/EcoRV-orf8, BglIIHI-orf9/EcoRV-orf9, BamHI-orf16/EcoRV-orf16, BamHI-orf20/EcoRV-orf20, BglIIHI-orf29/EcoRV-orf29, BglIIHI-orf31/EcoRV-orf31 and BglIIHI-M/EcoRV-M, respectively, and cloned in the designated restriction sites of plasmid pEFBA-oriT \[[@B80-marinedrugs-16-00259]\], downstream to the *aac*(*3*)*IV* gene. Then, the upstream sequence of the cited genes were likewise amplified with the primer pairs NsiI-orf8/SpeI-orf8, NsiI-orf9/SpeI-orf9, NsiI-orf16/SpeI-orf16, NsiI-orf20/SpeI-orf20, NsiI-orf29/SpeI-orf29, NsiI-orf31/SpeI-orf31 andNsiI-M/SpeI-M, respectively, and cloned upstream to the *aac*(*3*)*IV* gene. Finally, the hygromycin B resistance (Hyg^R^) gene marker, *hyg*, was extracted by XbaI/NheI digestion from plasmid pLHyg \[[@B81-marinedrugs-16-00259]\] and introduced in the XbaI site of the deletion plasmids. The resulting construction plasmids, pDorf8, pDorf9, pDorf16, pDorf20, pDorf29, pDorf31, pDjomM were introduced in *S.caniferus* GUA-06-05-006A to generate deletion strains ∆orf8-araC, ∆*orf9*, ∆*orf16-luxR*, ∆*orf20-marR*, ∆*orf29-gntR*, ∆*orf31* and ∆*jomM*, respectively. Gene *hyg* allowed recognizing clones in which a complete gene replacement by a double cross-over has taken place (Hyg^S^ Am^R^) from those in which a single cross-over event has integrated the deletion plasmid into the chromosome (Hyg^R^ Am^R^).

A suitable plasmid backbone to accomplish ectopic expression was constructed as follows. A 930 bp fragment containing the kanamycin resistance marker *aph*(*3*) *II* was amplified from plasmid pCAP01 \[[@B37-marinedrugs-16-00259]\] with primers EcoRI-KanR/EcoRV-KanR and cloned in the integrative plasmid pSETec \[[@B82-marinedrugs-16-00259]\], contiguous to the constitutive *ermE\*p* promoter to produce plasmid pSETk. Genes *orf8*, *orf16*, *orf20*, *orf29* and *jomM* were amplified with primers indicated in [Supplementary file 3: Table S1](#app1-marinedrugs-16-00259){ref-type="app"}, and cloned in pSETk between *ermE\*p* and *aph(3) II*. The resulting plasmids ([Supplementary file 3: Table S1](#app1-marinedrugs-16-00259){ref-type="app"}) were transferred to *S.caniferus* GUA-06-05-006A or ∆jomMto generate strains G-pSAraC, G-pSLuxR, G-pSMarR, G-pSGntR and ∆M-pSEJomM.

4.4. Heterologous Expression of the JAs BGC {#sec4dot4-marinedrugs-16-00259}
-------------------------------------------

The JAs BGC (*orf9* to *orf23*) was captured by TAR cloning \[[@B37-marinedrugs-16-00259]\] for heterologous expression in *S. coelicolor* M1152 and *S. albus* J1074. Cluster capture arms of approximately 1 Kb were generated by PCR amplification with primer pairs XhoI-2TAR/NsiI-U2TAR and NsiI-L2TAR/SpeI-2TAR ([Supplementary file 3: Table S1](#app1-marinedrugs-16-00259){ref-type="app"}). PCR products were digested with NsiI and ligated. The resulting assembled fragment of 2 Kb was then amplified with primers XhoI-2TAR/SpeI-2TAR and cloned in the XhoI/SpeI sites of plasmid pCAP01 to afford the capture plasmid pCL2-CAP. Yeast strain *Saccharomyces cerevisiae* VL6-48 was then co-transformed \[[@B76-marinedrugs-16-00259]\] with pCL2-CAP (0.5 μg), linearized by digestion with NsiI, and *S. caniferus*GUA-06-05-006A genomic DNA (1 μg). Yeast transformants were selected on synthetic YNB--trp medium and screened by PCR for the presence of the JAs BGC. The resulting plasmid, p2NTAR, was extracted from three positive clones, subjected to physical characterization by BamHI, NcoI, NotI, PstI and EcoRV digestion and transferred to the heterologous *Streptomyces* hosts by intergeneric conjugation \[[@B44-marinedrugs-16-00259]\].

To produce plasmid pNTARe, the *ermE\*p* promoter was integrated upstream of *jomP1*, in plasmid pJATAR, by ReDirect technology \[[@B83-marinedrugs-16-00259]\].The apramycin resistant gene marker *aac*(*3*)*IV* and *ermE\*p* were amplified from plasmid pSETec \[[@B82-marinedrugs-16-00259]\] with the primer pairs dApra/NsiI-rvApra and dNsiI-pErm/rvpErm, respectively. The PCR products were digested with NsiI and ligated. The resulting *aac*(*3*)*IV*-*ermE\*p* assembled fragment was then amplified with the primer pair dApra-pErm/rvApra-pErm to generate a DNA fragment flanked with suitable pJATAR homologous sequences to direct *ermE\*p* integration upstream of *jomP1*. This fragment and pJATAR were introduced in *E. coli* BW25113 as described in \[[@B83-marinedrugs-16-00259]\]. Kanamycin/apramycin resistant transformants were selected and analyzed for correct *ermE\*p* integration by sequencing with primers dNsiI-pErm, rvpErm, dApra and NsiI-rvApra.

4.5. Sequencing and Bioinformatics Analysis {#sec4dot5-marinedrugs-16-00259}
-------------------------------------------

The JAs BGC was identified and analyzed by the antibiotics and secondary metabolite analysis shell: antiSMASH 4.0 \[[@B84-marinedrugs-16-00259]\] and PRISM 3 \[[@B85-marinedrugs-16-00259],[@B86-marinedrugs-16-00259]\]. Annotation of ORFs within the JA BGC was based on database searching of the corresponding proteins carried out by BLAST algorithm \[[@B87-marinedrugs-16-00259]\] at the National Center for Biotechnology Information (NCBI). Additional sequence alignments were conducted by Clustal Omega \[[@B88-marinedrugs-16-00259]\] and EMBOSS Water \[[@B89-marinedrugs-16-00259]\] from the European Molecular Biology Laboratory (EMBL).

The nucleotide sequence of the jomthonic acids biosynthesis gene cluster was deposited in the European Nucleotide Archive (accession number: LT990689) and at Minimum Information about a Biosynthetic Gene Cluster (MIBiG) repository \[[@B90-marinedrugs-16-00259]\] under the accession BGC0001457.

4.6. Analysis of Metabolite Production and Compound Purification {#sec4dot6-marinedrugs-16-00259}
----------------------------------------------------------------

Whole culture samples (1 or 5 mL) were mixed with an equal volume of ethyl acetate and mixed on a rotary shaker at room temperature for 1 h. The organic phase was then recovered by centrifugation (3000× *g*, 10 min) and evaporated in vacuo. The resulting dry residue was dissolved in methanol:DMSO (1:1) to perform UPLC and LC-MS analyses as described elsewhere \[[@B91-marinedrugs-16-00259],[@B92-marinedrugs-16-00259]\].

Compounds **1**--**3** were purified from 2.5 L of G-p*ermE*\* culture supernatant. Culture was filtered and then applied to a solid-phase extraction cartridge (Sep-Pak Vac C18, 10 g, Waters, Mildford, MA, USA) that had been fitted with a perforated stopper pierced by a stainless steel HPLC (Waters, Mildford, MA, USA) tubing. The culture broth was applied by means of a peristaltic pump and subsequently the cartridge was connected to a HPLC quaternary pump (model 600E, Waters). The retained material was eluted with a mixture of methanol and 0.05% trifluoroacetic acid (TFA) in water. A linear gradient from 0 to 100% methanol in 60 min, at 10 mL/min, was used. Fractions were taken every 5 min, collected on 5 mL of 0.1 M phosphate buffer, pH 7.0 and analyzed by UPLC. Fractions containing the desired compounds were evaporated in vacuo and subsequently re-dissolved in a small volume of a DMSO:methanol (50:50) mixture. Compounds of interest were then purified by preparative HPLC using a SunFire C18 column (10 µm, 10 × 250 mm, Waters, Mildford, MA, USA). Organic extracts were chromatographed with mixtures of acetonitrile or methanol and 0.1% TFA in accurate isocratic conditions (7 mL/min), and collected on 0.1 M phosphate buffer (pH 7.0). After every purification step, the collected compounds were diluted 4-fold with water and then applied to a solid-phase extraction cartridge (Sep-Pak C18, Waters, Mildford, MA, USA). The cartridges were washed with water and compounds were eluted with methanol and dried in vacuo. Once the purification was finished, the compounds were dissolved in a mixture of tert-butanol and water (1:1) and lyophilized, obtaining 21.9, 3.8 and 3.9 mg of compounds 1, 2 and 3, respectively.

4.7. Mass Spectra and Structural Elucidation {#sec4dot7-marinedrugs-16-00259}
--------------------------------------------

NMR spectra were obtained on a Varian "Unity 500" spectrometer (Agilent Technologies, Palo Alto, CA, USA) at 500/125 MHz (1H/13C) and on a Varian "Unity 400" spectrometer (Agilent Technologies, Palo Alto, CA, USA) at 400/100 MHz (1H/13C). Chemical shifts were reported in ppm using residual CDCl3 (δ 7.26 ppm for 1H and 77.0 ppm for 13C) as an internal reference. COSY, HSQC and HMBC experiments were performed using standard pulse sequences. Data were processed using MestReNova software (Mnova, Santiago de Compostela, Spain). (+)ESIMS were recorded using an Agilent 1100 Series LC/MS spectrometer (Agilent Technologies, Palo Alto, CA, USA). High resolution mass spectroscopy (HRMS) was performed on an Agilent 6230 TOF LC/MS system (Agilent Technologies, Palo Alto, CA, USA) using the electrospray ionization mass spectrometry (ESI-MS) technique.
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![Organization of the jomthonic acids biosynthetic gene cluster. The proposed gene functions are listed in [Table 1](#marinedrugs-16-00259-t001){ref-type="table"}. Grey bar indicates DNA fragment cloned in plasmid pJATAR for heterologous expression.](marinedrugs-16-00259-g001){#marinedrugs-16-00259-f001}

![Activation of jomthonic acids biosynthesis. (**A**) Metabolite analysis by UPLC of *Streptomyces caniferus* GUA-06-05-006A (wild type), G-p*erm\**strain (constitutive promoter *ermE\*p* inserted) and mutants Δ*jomP1* and Δ*jomN*. Peaks corresponding to PM100117 (PM17) and PM100118 (PM18) are indicated. (**B**) Chemical structures of jomthonic acid A and novel derivatives D and E. Asterisks indicate structural differences among the three compounds.](marinedrugs-16-00259-g002){#marinedrugs-16-00259-f002}

![Proposed biosynthesis pathway of jomthonic acids. Polyketide synthase (*JomP1* and *JomP2*) and non-ribosomal protein synthetase (*JomN*) domains are as follows: KS ketosynthase, AT acyltransferase, KR ketoreductase, DH dehydratase, ACP acyl-carrier-protein, C condensation, Aadenylation, PCP peptidyl carrier protein. Compounds not detected in *S. caniferus* GUA-06-05-006A are shown in grey. Parentheses indicate structures not confirmed by NMR. Genes coding for enzymes X~1~, X~2~ and X~3~ were not identified in the biosynthesis gene cluster.](marinedrugs-16-00259-g003){#marinedrugs-16-00259-f003}

![Deletion of *jomM* and genes potentially involved in JA D and E biosynthesis. UPLC analysis of jomthonic acids biosynthesis in *Streptomyces caniferus* GUA-06-05-006A (wild type) and mutant strains ∆*orf31*, ∆*orf9* and ∆*jomM*. Peaks corresponding to PM100117 (PM17) and PM100118 (PM18) are indicated.](marinedrugs-16-00259-g004){#marinedrugs-16-00259-f004}

![Cluster boundaries analysis. UPLC analysis of jomthonic acids production in (**A**) *Streptomyces caniferus* GUA-06-05-006A (wild type) and mutant strains ∆*orf29-gntR*, ∆*orf20-marR*, ∆*orf16-luxR* and ∆*orf8-araC*, and (**B**) *Streptomyces caniferus* GUA-06-05-006A carrying overexpression plasmids pSETk (empty plasmid), pSEGntR (*orf29*), pSEMarR (*orf20*), pSESARP (*orf16*) and pSEAraC (*orf8*). Peaks corresponding to PM100117 (PM17) and PM100118 (PM18) are indicated.](marinedrugs-16-00259-g005){#marinedrugs-16-00259-f005}

![Heterologous expression of the jomthonic acids biosynthesis gene cluster. UPLC metabolite analysis of (**A**) *Streptomyces coelicolor* M1152 and (**B**) *Streptomyces albus* J1074 carrying plasmid pCAP01 (empty plasmid), pJATAR (JAs BGC) and pJATARe (JAs BGC with *ermE\**pinserted). (**C**) Speculative chemical structure of peaks 2^a^ (jomthonic acids B or C) in *S. albus* J1074.](marinedrugs-16-00259-g006){#marinedrugs-16-00259-f006}

marinedrugs-16-00259-t001_Table 1

###### 

Deduced functions of open reading frames (ORFs) in jomthonic acids biosynthetic gene cluster.

  Gene      Deduced aa. Length   Protein Homologue (Accession No.)   Identity/Similarity (%)   Proposed Function
  --------- -------------------- ----------------------------------- ------------------------- --------------------------------------------------
  *orf1*    194                  WP_030077520.1                      93/86                     RNA polymerase
  *orf2*    313                  WP_053208602.1                      95/96                     Hypothetical protein
  *orf3*    1462                 WP_084771961.1                      94/96                     Cell division protein FtsK
  *orf4*    1525                 WP_055485092.1                      59/70                     Type IV secretion protein Rhs
  *orf5*    241                  WP_084771964.1                      93/95                     Hypothetical protein
  *orf6*    104                  WP_084771965.1                      86/94                     Hypothetical protein
  *orf7*    99                   WP_033268020.1                      99/100                    WXG-like protein
  *orf8*    289                  SDQ83237.1                          89/91                     AraC-family transcriptional regulator
  *orf9*    396                  SDQ83203.1                          87/93                     Monooxygenase
  *orf10*   315                  OSY47464.1                          92/94                     FG-GAP repeat protein
  *orf11*   95                   OSY47461.1                          96/96                     Type II toxin--antitoxin system
  *orf12*   286                  OSY47460.1                          91/94                     Thioesterase
  *orf13*   218                  WP_085923163.1                      99/99                     ATP-dependent Clp protease proteolytic subunit
  *orf14*   106                  OSY47458.1                          95/97                     Hypothetical protein
  *orf15*                        \-                                  \-                        Unassigned
  *jomP1*   2093                 WP_020735335.1                      47/58                     Type I polyketide synthase (PCP/KS/AT/AT/KR/PCP)
  *jomP2*   1853                 CAD19087.1                          43/57                     Type I polyketide synthase (KS/AT/DH/KR/PCP)
  *jomN*    1062                 SCL52665.1                          48/63                     Non-ribosomal protein synthetase(C/A/PCP)
  *jomT*    254                  WP_025675064.1                      35/51                     Thioesterase
  *jomB*    72                   WP_004933768.1                      72/83                     *mbt*H-like protein
  *jomM*    329                  WP_004933770.1                      78/85                     Methyltransferase
  *orf16*   751                  WP_053684324.1                      53/65                     LuxR-family transcriptional regulator
  *orf17*   229                  WP_042159102.1                      83/88                     Hypothetical protein
  *orf18*   404                  WP_052718894.1                      90/93                     Hypothetical protein
  *orf19*   295                  SCK58100.1                          86/91                     Putative nuclease
  *orf20*   170                  WP_035838695.1                      81/85                     MarR-family transcriptional regulator
  *orf21*   123                  WP_039639044.1                      93/95                     Glyoxalase
  *orf22*   318                  WP_042157776.1                      78/83                     DNA-3-methyladenine glycosylase 2 family protein
  *rf23*    190                  WP_042159103.1                      97/99                     Hypotheticalprotein
  *orf24*   373                  WP_042159104.1                      99/100                    ROK-familyglucokinase
  *orf25*   269                  WP_085927837.1                      100/100                   Sugar ABC transporter ATP-binding protein
  *orf26*   356                  WP_085927838.1                      99/99                     Ribose ABC transporter permease
  *orf27*   337                  WP_042159107.1                      99/100                    Sugar ABC transporter substrate-binding protein
  *orf28*   358                  WP_042159108.1                      96/97                     Sugar ABC transporter substrate-binding protein
  *orf29*   258                  GAO11207.1                          98/99                     GntR-family transcriptional regulator
  *orf30*   126                  WP_018092820.1                      84/90                     Glyoxalase
  *orf31*   275                  WP_042159111.1                      95/96                     Putative aminoacid ABC transporter
  *orf32*   219                  WP_085927844.1                      99/99                     2-dehydro-3-deoxy-phosphogluconate aldolase
